General Announcement::Board Meeting

Issuer & Securities

Issuer/ Manager: GLENMARK PHARMACEUTICALS LIMITED
Securities: GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security: No

Announcement Title: General Announcement
Date &Time of Broadcast: 03-May-2017 14:58:01
Status: New
Announcement Sub Title: Board Meeting
Announcement Reference: SG170503OTHRZIF1
Submitted By (Co./ Ind. Name): Glenmark Pharmaceuticals Limited
Designation: Company Secretary & Compliance Officer
Effective Date and Time of the event: 02/05/2017 17:00:00
Description (Please provide a detailed description of the event in the box below): We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations And Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Thursday, May 11, 2017 to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the year ended March 31, 2017 and to consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2017.

Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from March 24, 2017 to May 15, 2017 (both days inclusive) for the purpose of approval of Standalone and Consolidated Audited Financial Results for the Year ended March 31, 2017.

Total size =595K